INTRODUCTION {#S1}
============

The skin is a crucial immunological organ and acts as a first line of physical and immunological defense. Interleukin-17 (IL-17) and its family cytokines have been shown to be essential in controlling this process. Although the cellular sources of IL-17 have been increasingly added, we and others have demonstrated that innate, dermal γδT cells are the major IL-17 producers (γδT17) in the skin and play an essential role in skin inflammation ([@R3]; [@R51]). The critical role of dermal γδT17 cells in skin inflammation has been further demonstrated by many other studies ([@R16]; [@R25]; [@R33]; [@R41]; [@R46]; [@R57]). We have also shown that dermal γδT17 cells have a unique developmental requirement, which is different from γδT cells from other anatomical sites ([@R4]). However, the underlying factors that regulate dermal γδT17 cells in the steady condition and skin inflammation have not been fully defined. Previous studies have shown that cytokines IL-1β and IL-23 stimulate γδ T cells for IL-17 production ([@R52]) and promote γδT17 cell development from peripheral CD27^+^CD122^−^ γδT cells ([@R38]). IL-23 has also been shown to drive peripheral γδT17 cell differentiation and expansion ([@R42]). Additionally, cytokine IL-7 can promote mouse and human γδT17 expansion ([@R36]). Certain pathogens also directly interact with γδT cells to induce IL-17 production ([@R35]). Besides innate stimuli, activation of TCR signaling on γδT cells further enhances cytokine-induced IL-17 production from γδT cells ([@R36]; [@R52]; [@R59]). Despite these progresses made with γδT17 cells, little is known about the molecular pathways that regulate dermal γδT17 cell effector function.

The mechanistic or mammalian target of rapamycin (mTOR) signaling pathway plays a critical role in T cell proliferation, differentiation, and effector functions ([@R27]; [@R58]; [@R60]). The serine and/or threonine kinase mTOR consists of two distinct complexes: mTOR complex 1 (mTORC1) and 2 (mTORC2). The Raptor (regulatory associated protein of mTOR) is associated with mTORC1, whereas Rictor (rapamycin-insensitive companion of mTOR) is part of complex mTORC2. The ribosomal p70S6 kinase (p70S6K) and the 4E-binding protein 1 (4EBP1) are downstream of mTORC1 and mTORC2 controls AKT, SGK1, and protein kinase Cα (PKCα). Recent studies have demonstrated that the phosphatidylinositol 3-kinase (PI3K)-AKT-mTORC1-S6K axis positively regulates Th17 cell differentiation by promoting transcription factor RORγt nuclear translocation ([@R24]; [@R26]). In addition, the mTOR signaling pathway plays a role in the proliferation of epidermal keratinocytes and angiogenesis ([@R19]; [@R45]), hallmarks of psoriasis pathogenesis. Recent studies also show that lack of mTORC1 promotes γδT cell generation ([@R56]), and transcription factor c-Maf is essential for γδT17 cell differentiation and maintenance ([@R61]). In the case of skin wound healing, inhibition of the mTOR pathway by rapamycin treatment suppresses proliferation of resident γδT cells, but not keratinocytes ([@R37]). However, it is unknown whether the mTOR pathway regulates dermal γδT cells, particularly dermal γδT17 cells in skin inflammation.

In the current study, we investigate the signaling pathways that are essential in dermal γδT17 cell effector function. We show that both IL-1R and IL-23R pathways are needed for dermal γδT17 cell activation, although IL-1R is also critically involved in dermal γδT17 cell expansion. Mechanistically, IL-1β activates the mTOR signaling pathway via IL-1R-MyD88, whereas IL-23 activates the STAT3 pathway. Further studies show that although both mTORC1 and mTORC2 are critical in dermal γδT17 cell expansion, IL-17 production in dermal γδT cells is abrogated in mTORC2-deficient mice. This is associated with increased dysfunctional mitochondria and mitochondria reactive oxygen species (ROS) production. On the contrary, IL-23 stimulates STAT3 activation, which is critical in dermal Vγ4 effector function, whereas dermal Vγ6 effector function is independent of the STAT3 pathway. Transcription factor IRF-4 appears to link the IL-1R and IL-23R pathways to induce enhanced IL-17 production in dermal γδ T cells. Consequently, skin inflammation is drastically reduced in mTORC2-deficient mice, but not in STAT3-deficient mice. Thus, our study reveals a critical molecular mechanism by which dermal γδ T cells are activated for effector function.

RESULTS {#S2}
=======

Dermal γδT Cell IL-17 Production and Expansion Require IL-1R and IL-23R Signaling Pathways {#S3}
------------------------------------------------------------------------------------------

Psoriasis is an autoinflammatory skin disease affecting approximately 2% of the population worldwide. Inflammatory cytokines including IL-23 and IL-1 have been shown to be critical in regulating disease pathogenesis ([@R12]). We used RNA-based next-generation sequencing (RNA-seq) to analyze lesional skin samples from psoriasis patients effectively treated with glucocorticoid. Gene set enrichment analysis (GSEA) revealed that regulation of IL-12 production genes, including IL-23 and IL-23R, and IL-1R signaling pathway-related genes was downregulated in patients effectively treated with glucocorticoid ([Figure 1A](#F1){ref-type="fig"}), suggesting that these two pathways are related to not only disease pathogenesis but also treatment response. Previous studies have shown that cytokine IL-17 plays a critical role in psoriasis pathogenesis ([@R30]), IL-1β and IL-23 are essential to promote extrathymic commitment of γδT17 cells ([@R38]), and IL-23 drives peripheral γδT17 differentiation ([@R42]). In mouse skin, dermal γδT cells are the major cellular source of IL-17 and play a critical role in skin inflammation. Therefore, we examined dermal γδT cell response upon IL-1β and IL-23 stimulation. Combined IL-1β and IL-23 indeed induced enhanced IL-17 production in dermal γδT cells ([Figure S1](#SD1){ref-type="supplementary-material"}). This was the case for both dermal Vγ4 and Vγ6 T cells ([Figure 1B](#F1){ref-type="fig"}), two main subsets of γδT cells in the skin ([@R4]). The IL-17 production from dermal γδT cells including Vγ4 and Vγ6 T cells was significantly reduced in IL-1R or IL-23R knockout (KO) mice ([Figure S1](#SD1){ref-type="supplementary-material"}; [Figures 1B](#F1){ref-type="fig"} and [1C](#F1){ref-type="fig"}). We next examined dermal γδT cell *in vitro* expansion in the presence of IL-1β and/or IL-23. Although IL-23 alone stimulated dermal γδ T cell proliferation, this effect was abrogated in IL-1R KO mice, whereas IL-1β-induced dermal γδT cell proliferation was only partly diminished in IL-23R KO mice ([Figure S1](#SD1){ref-type="supplementary-material"}; [Figure 1D](#F1){ref-type="fig"}), suggesting a differential signaling requirement for dermal γδT cell expansion. This was particularly the case for dermal Vγ4 T cells ([Figures 1B](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}).

IL-1β Stimulates Dermal γδT Cell Proliferation and IL-17 Production via the mTOR Signaling Pathway {#S4}
--------------------------------------------------------------------------------------------------

Because the IL-1β/IL-1R axis is critical in dermal γδT cell expansion and IL-17 production, we next examined the underlying molecular mechanism by which IL-1β induces dermal γδT cell effector function. Dermal γδT cells constitutively expressed p-mTOR, but not p-STAT3, as assessed by Phosflow analysis ([Figure 2A](#F2){ref-type="fig"}). IL-1β stimulation enhanced phosphorylation of mTOR, whereas IL-23 induced STAT3 activation in dermal γδT cells. This was also confirmed by western blot analysis ([Figure 2B](#F2){ref-type="fig"}) and confocal microscopy ([Figure 2C](#F2){ref-type="fig"}). Combined IL-1β with IL-23 did not show enhanced p-mTOR or p-STAT3 ([Figure 2B](#F2){ref-type="fig"}). Notably, IL-1β-induced p-mTOR expression was completely abrogated in IL-1R KO mice, but not drastically altered in IL-23R KO mice, whereas IL-23-induced p-STAT3 was not changed in IL-1R KO mice but was abrogated in IL-23R KO mice ([Figure 2D](#F2){ref-type="fig"}). To investigate whether indeed the mTOR signaling plays a critical role in dermal γδT cell function, skin cells were labeled with carboxyfluorescein succinimidyl ester (CFSE) and stimulated with IL-1β and IL-23 in the presence or absence of the mTOR inhibitor rapamycin. As depicted in [Figure 2E](#F2){ref-type="fig"}, rapamycin treatment significantly decreased dermal γδT cell *in vitro* proliferation and IL-17 production induced by IL-1β and IL-23.

mTORC2 Is Critical in IL-1β-Induced Dermal γδT Cell Effector Function {#S5}
---------------------------------------------------------------------

The mTOR exists in two distinct complexes, mTORC1 and mTORC2, which contain scaffold protein Raptor or Rictor, respectively. mTORC1 induces phosphorylation of 4E-BP1 and p70-S6 kinase leading to transcriptional regulation ([@R21]), whereas mTORC2 induces phosphorylation and feedback activation of AKT ([@R47]). Previous studies have shown that mTORC1 and mTORC2 have distinct functions in directing CD4 T cell differentiation and function ([@R28]). Although mTORC1 is sensitive to rapamycin, mTORC2 can also be inhibited by a prolonged or high dose of rapamycin in CD4 T cells ([@R11]; [@R48]). Therefore, we examined mTORC1 and mTORC2 activation in dermal γδT cells. IL-1β-induced phosphorylation of AKT and S6 was revealed by western blot analysis ([Figure 3A](#F3){ref-type="fig"}). This was also confirmed by Phosflow analysis ([Figure 3B](#F3){ref-type="fig"}). We next used CD2-cre;Raptor^*fl/fl*^ and Rictor^*fl/fl*^ mice to assess relative contributions of mTORC1 and mTORC2 in dermal γδT cell effector function. In CD2-cre;Raptor^*fl/fl*^ mice, the overall T cells in the skin including γδT cells, dermal γδT cells, and epidermal γδT cells were not significantly altered compared with control mice, although dermal Vγ4 T cells were decreased, whereas Vγ6 T cells were increased ([Figure S2A](#SD1){ref-type="supplementary-material"}). In contrast, these mice had increased CD3^+^ T cells and γδT cells and decreased Vγ4, but increased Vγ6 in the peripheral lymph nodes ([Figure S2B](#SD1){ref-type="supplementary-material"}), suggesting that mTORC1 plays a critical role in peripheral γδT cell homeostasis. Deletion of Raptor in dermal γδT cells abrogated phosphor-S6 activation by IL-1β stimulation ([Figure S3A](#SD1){ref-type="supplementary-material"}). Dermal γδT cells showed significantly decreased *in vitro* proliferation upon IL-1β stimulation in *CD2-cre; Raptor*^*f/f*^ mice ([Figure S3B](#SD1){ref-type="supplementary-material"}). However, dermal γδT cell IL-17 production in *CD2-cre; Raptor*^*f/f*^ mice was not affected ([Figure S3C](#SD1){ref-type="supplementary-material"}).

Similarly, different T cell subsets in the skin of CD2-cre;Rictor^*fl/fl*^ and Rictor^*fl/fl*^ mice were not significantly altered, although dermal Vγ4 T cells were decreased whereas Vγ6 T cells were increased in Rictor conditional KO (cKO) mice ([Figure S2C](#SD1){ref-type="supplementary-material"}). Rictor cKO mice also had increased γδT cells, although both Vγ4 and Vγ6 were decreased, but Vγ1 increased in the peripheral lymph nodes ([Figure S2D](#SD1){ref-type="supplementary-material"}). Deletion of Rictor in dermal γδT cells abrogated phosphor-AKT activation upon IL-1β stimulation ([Figure 3C](#F3){ref-type="fig"}). Dermal γδT cell proliferation and IL-17 production were significantly diminished in *CD2-cre; Rictor*^*f/f*^ mice ([Figures 3D](#F3){ref-type="fig"} and [3E](#F3){ref-type="fig"}) upon IL-1β or IL-1β plus IL-23 stimulation. This was for both Vγ4 and Vγ6 T cells (data not shown). The gating strategy was shown in [Figure S3D](#SD1){ref-type="supplementary-material"}. However, IL-23-induced STAT3 phosphorylation was not affected in *CD2-cre; Rictor*^*f/f*^ or *Raptor*^*f/f*^ mice ([Figure 3F](#F3){ref-type="fig"}), suggesting that mTORC2 is essential in IL-1β-induced dermal γδT cell effector function.

MyD88 Is Required for IL-1β-Induced mTOR Activation in Dermal γδT Cells {#S6}
-----------------------------------------------------------------------

Previous studies have shown that MyD88 is essential to sustain the mTOR activity, thus promoting Th17 cell proliferation ([@R7]). In addition, IL-1β promotes granulocyte-macrophage colony-stimulating factor (GM-CSF) production in αβ and γδT cells via MyD88 ([@R32]). To further delineate the possible role of MyD88 in IL-17-producing dermal γδT cell differentiation and activation, we first examined dermal γδT cells from MyD88 KO mice and IL-1R KO mice. Notably, dermal γδT cell frequency was not altered in IL-1R KO mice but was significantly decreased in MyD88 KO mice ([Figure S4A](#SD1){ref-type="supplementary-material"}). In addition, IL-17-producing dermal γδT cells were decreased in both IL-1R KO and MyD88 KO mice. We next examined dermal γδT cell proliferation and IL-17 production upon IL-1β or IL-1β plus IL-23 stimulation. As shown in [Figure S4B](#SD1){ref-type="supplementary-material"}, IL-1β-induced dermal γδT cell proliferation and IL-17 production were completely abrogated in MyD88 KO mice. Further Phosflow analysis revealed that IL-23-induced STAT3 phosphorylation was not impaired in IL-1R KO or MyD88 KO mice ([Figure S4C](#SD1){ref-type="supplementary-material"}). In contrast, IL-1β-induced phosphorylation of AKT and S6 was completely abrogated in IL-1R and MyD88 KO mice, suggesting that IL-1β-induced mTOR activation requires MyD88, whereas IL-23-induced STAT3 activation is independent on the IL-1R-MyD88 pathway.

mTORC2 Deficiency Induces Accumulation of Dysfunctional Mitochondria {#S7}
--------------------------------------------------------------------

Because mTOR signaling plays a critical role in cellular metabolism, we reasoned that the abrogated IL-17 production and proliferation in mTORC2-deficient γδT cells may be caused by altered metabolic profiles. IL-17-producing γδT cells predominately used an oxidative phosphorylation pathway for energy fuel because inhibition of isocitrate dehydrogenase (IDH) by AGI and pyruvate kinase (PK) by oxalate (OXA) significantly diminished IL-17 production from γδT cells ([Figure 4A](#F4){ref-type="fig"}). 2-Deoxyglucose (2-DG) acts to competitively inhibit glycolysis. Addition of 2-DG, however, showed no impact on IL-17 production. We then examined enzymes that are related to glucose metabolism, and found no substantial differences between Rictor cKO and control mice ([Figure 4B](#F4){ref-type="fig"}). Furthermore, we did not find differences of glucose uptake among Raptor or Rictor cKO mice and corresponding control mice as measured by 2--2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (NBDG) staining ([Figure 4C](#F4){ref-type="fig"}). 2-NBDG is a fluorescent glucose analog that has been used to determine glucose uptake. We next investigated whether the altered metabolic profiles of mitochondria are responsible for the deceased IL-17 production in Rictor cKO dermal γδT cells. We stained dermal γδT cells with MitoTracker Green and MitoTracker Red to distinguish between respiring mitochondria (MitoTracker Red^+^) and dysfunctional mitochondria (MitoTracker Green^+/high^, MitoTracker Red^+/low^) ([@R22]). We observed an increase in dysfunctional mitochondria but decrease in respiring mitochondria in Rictor cKO dermal γδT cells compared with those in control mice ([Figure 4D](#F4){ref-type="fig"}). However, no differences were noted in Raptor cKO dermal γδT cells ([Figure 4D](#F4){ref-type="fig"}). These data suggest that decreased respiring mitochondria may account for the decreased IL-17 production in Rictor cKO dermal γδT cells.

Loss of mitochondria membrane potential (ΔΨm) is associated with accumulation of mitochondrial ROS. We thus examined whether accumulation of dysfunctional mitochondria (ΔΨm^low^) in Rictor cKO dermal γδ T cells was associated with production of mitochondrial ROS. To assess ROS levels in the mitochondria, we used the mitochondria-specific ROS indicator MitoSOX to detect superoxide in the mitochondria of live cells. We found that MitoSOX-positive cells were significantly higher in Rictor-deficient dermal γδT cells than those in control mice ([Figure 4E](#F4){ref-type="fig"}). In addition, the overall ROS production determined by 2′,7'-dichlorodihydrofluorescein diacetate (DCFDA) assay in dermal γδT cells from Rictor cKO mice was also higher than control mice ([Figure 4F](#F4){ref-type="fig"}). To further support this notion, we found that addition of the ROS inhibitor N-acetylcysteine (NAC) could rescue IL-17 production by dermal γδT cells from Rictor cKO mice ([Figure 4G](#F4){ref-type="fig"}). Taken together, these findings suggest that Rictor deficiency in dermal γδT cells may result in the elevated production of ROS, consequently leading to reduced respiring mitochondria function and IL-17 production.

Because IL-1β-induced mTORC2 activation is through MyD88, we thus examined whether dermal γδT cells from MyD88 KO mice had a similar defect on mitochondrial function and excessive ROS production. Similar to Rictor cKO mice, dermal γδT cells from MyD88 KO mice had decreased respiring mitochondria function ([Figure S5A](#SD1){ref-type="supplementary-material"}) and increased ROS production as compared with wild-type (WT) mice ([Figure S5B](#SD1){ref-type="supplementary-material"}). No difference was noticed for glucose uptake as assessed by 2-NBDG binding assay ([Figure S5C](#SD1){ref-type="supplementary-material"}), consistent with Rictor cKO mice. These data further support the notion that the IL-1β-MyD88-mTORC2 pathway is critical in regulating dermal γδT17 cell function.

IL-23-Mediated STAT3 Signaling Differentially Regulates Vγ4 and Vγ6 Dermal γδT Cell Effector Function {#S8}
-----------------------------------------------------------------------------------------------------

Because IL-23 induces STAT3 activation, we next examined how dermal γδT cell activation is impacted by STAT3 signaling. Skin cells from STAT3 control and cKO mice were stimulated with IL-1β and/or IL-23. The gating strategy was described in [Figure S6A](#SD1){ref-type="supplementary-material"}. IL-23- or IL-1β-induced dermal γδT cell proliferation was lower in *CD2-cre;STAT3*^*f/f*^ mice ([Figure S6B](#SD1){ref-type="supplementary-material"}), but IL-17 production was not significantly altered ([Figure 5A](#F5){ref-type="fig"}). It appeared that dermal γδT cells from *CD2-cre;STAT3*^*f/f*^ mice produced even more IL-17 in the presence of both IL-1β and IL-23 ([Figure 5A](#F5){ref-type="fig"}). However, when we gated on the different subsets of dermal γδT cells, we found that dermal Vγ4 T cell proliferation in response to IL-23 stimulation and IL-17 production by IL-1β and/or IL-23 was drastically reduced in *CD2-cre;STAT3*^*f/f*^ mice ([Figure S6C](#SD1){ref-type="supplementary-material"}; [Figure 5A](#F5){ref-type="fig"}). In contrast, dermal Vγ6 T cell IL-17 production was somewhat enhanced in *CD2-cre;STAT3*^*f/f*^ mice ([Figure 5A](#F5){ref-type="fig"}), although dermal Vγ6 T cell proliferation was not significantly altered ([Figure S6D](#SD1){ref-type="supplementary-material"}). We next examined whether mTOR phosphorylation and STAT3 activation in dermal Vγ4 and Vγ6 T cells are different in *CD2-cre;STAT3*^*f/f*^ mice. As shown in [Figure 5B](#F5){ref-type="fig"}, dermal Vγ4 and Vγ6 displayed similar levels of mTOR activation upon IL-1β stimulation. In addition, IL-23-induced STAT3 activation was similarly enhanced in dermal Vγ4 and Vγ6 T cells. These data suggest that STAT3 signal activated by IL-23 differentially regulates effector functions of different subsets of dermal γδT cells.

IL-1R Is Downregulated in STAT3-Deficient Vγ4 T Cells, and IRF-4 Links IL-1R and IL-23R Signaling Pathways for IL-17 Production {#S9}
-------------------------------------------------------------------------------------------------------------------------------

Previous data from the Immunological Genome (ImmGen) Project have shown that the IL-17-producing immature Vγ4 T cells (ImmV4e17) and Vγ6 T cells (ImmV6e17) from fetal mice had very similar global gene expression profiles ([@R39]). Further analysis showed that 70 genes were differentially expressed on these two subsets (1.5-fold cutoff; [Figure 6A](#F6){ref-type="fig"}). Notably, immV6e17 expressed higher mRNA levels of IL-1R, IL-23R, and IL-7R as compared with immV4e17 ([Figure 6B](#F6){ref-type="fig"}). Indeed, dermal Vγ6 T cells expressed higher levels of IL-1R and IL-23R compared with dermal Vγ4 T cells assessed by flow cytometry ([Figure 6C](#F6){ref-type="fig"}). These data led us to examine whether these receptor expression levels could be regulated differently by STAT3 in dermal Vγ4 and Vγ6 T cells. To this end, we stimulated them with IL-23 or IL-1β+IL-23 and then examined IL-1R and IL-23R expression levels. As shown in [Figure 6D](#F6){ref-type="fig"}, IL-1R mRNA expression level was significantly increased in dermal Vγ4 T cells upon IL-23 stimulation, but not in Vγ6 T cells. Strikingly, the increased IL-1R expression was completely abrogated in dermal Vγ4 T cells from STAT3 cKO mice. However, IL-1R expression on Vγ6 T cells was not altered upon IL-23 stimulation and even was higher in STAT3 cKO mice upon IL-1β and IL-23 stimulation. This was also confirmed by flow cytometry analysis ([Figure 6E](#F6){ref-type="fig"}). In contrast, IL-23R expression was not altered by STAT3 deficiency in both dermal Vγ4 and Vγ6 T cells (data not shown). These findings may explain the differential roles of STAT3 in regulating dermal Vγ4 and Vγ6 effector T cell function.

Next, we examined which transcription factor could link IL-1R and IL-23R signaling pathways for IL-17 production in dermal γδT cells. Transcription factor IRF-4 has been reported previously to play a critical role in Th17 cell differentiation and effector function ([@R40]). We found that IRF-4 mRNA expression level was increased upon IL-1β plus IL-23 stimulation in both dermal Vγ4 and Vγ6 T cells, but IL-23 alone did not stimulate elevated IRF-4 expression ([Figure 6F](#F6){ref-type="fig"}). The increased IRF-4 expression was significantly reduced in dermal Vγ4T cells due to STAT3 deficiency. We also found that IRF-4 mRNA expression was elevated upon IL-1β stimulation, and the elevated IRF-4 expression was abrogated in dermal γδT cells from mTORC2 mice, but not mTORC1 mice ([Figure 6G](#F6){ref-type="fig"}). To further determine the role of IRF-4 in dermal γδ T cells, we used IRF-4 small interfering RNA (siRNA) to knock down IRF-4 expression in dermal γδ T cells. Notably, knockdown of IRF-4 significantly reduced IL-17 production from dermal γδ T cells ([Figure 6H](#F6){ref-type="fig"}).

Skin Inflammation Is Reduced in mTORC2-Deficient Mice, but Not in STAT3-Deficient Mice {#S10}
--------------------------------------------------------------------------------------

Dermal γδT cells play a critical role in skin inflammation. Because mTORC2 has been shown to play an essential role in dermal γδT cell effector function *in vitro,* we examined whether skin inflammation is also impacted by mTORC2 deficiency in mice. In contrast, STAT3 deficiency did not impact on the overall dermal γδT cell effector function, but dermal Vγ4 and Vγ6 T cells were differentially regulated. To this end, we used an imiquimod (IMQ)-induced psoriasis-like mouse model in both strains. Histopathologically, mTORC2-deficient mice had significantly decreased epidermal thickness and neutrophil infiltration as compared with control mice ([Figure 7A](#F7){ref-type="fig"}). The mRNA levels of IL-17 and TNF-α in the skin were also significantly decreased ([Figure 7B](#F7){ref-type="fig"}). In contrast, no significant difference in epidermal thickness and neutrophil infiltration was observed between STAT3 cKO mice ([Figure 7C](#F7){ref-type="fig"}). We also examined *in vivo* 5-bromo-2′-deoxyuridine (BrdU) incorporation to stain proliferating cells in the skin. The gating strategy was shown in [Figure S7A](#SD1){ref-type="supplementary-material"}. The BrdU incorporation in both dermal Vγ4 and Vγ6 T cells, as well as αβT cells, was significantly decreased in Rictor cKO mice as compared with those in control mice ([Figure 7D](#F7){ref-type="fig"}; [Figure S7C](#SD1){ref-type="supplementary-material"}). Because dermal γδT cells accounted for more than 95% of IL-17-producing T cells in the skin ([Figure S7B](#SD1){ref-type="supplementary-material"}), we examined spontaneous IL-17 production from dermal γδT cells. Consistent with *in vitro* observation, total dermal γδT cells as well as Vγ4 and Vγ6 T cell IL-17 production were significantly reduced in Rictor cKO mice ([Figure 7D](#F7){ref-type="fig"}; [Figure S7C](#SD1){ref-type="supplementary-material"}). In contrast, BrdU incorporation was significantly reduced in dermal Vγ4, but not Vγ6 or αβT cells, in STAT3 cKO mice ([Figure 7E](#F7){ref-type="fig"}; [Figure S7D](#SD1){ref-type="supplementary-material"}). Similarly, IL-17 production from total dermal γδT cells was not altered ([Figure S7D](#SD1){ref-type="supplementary-material"}). However, IL-17 production from dermal Vγ4, but not Vγ6, was significantly reduced in STAT3 cKO mice ([Figure 7E](#F7){ref-type="fig"}). Taken together, these data support the notion that mTORC2 and STAT3 signaling pathways differentially regulate different subsets of dermal γδT effector function *in vivo* leading to distinct outcomes in skin inflammation.

DISCUSSION {#S11}
==========

Innate stimuli are essential to activate Th17 cells and γδT17 cells. Among these, cytokines including IL-1β and IL-23 have been shown to promote Th17 cell initiation, differentiation, and stabilization ([@R7]). These cytokines also promote innate γδT cells for enhanced IL-17 production and drive γδT17 cell differentiation and effector function ([@R38]; [@R42]; [@R52]). Although the underlying molecular mechanisms of these cytokines to promote Th17 cell development and function have been well defined ([@R53]), how these cytokines induce γδT17 cell effector function remains elusive. The aim of the current study is to investigate the underlying molecular pathways by which dermal γδT17 cells are activated and differentiated. Dermal γδT17 cells have been implicated to be critical in skin inflammatory disease such as psoriasis pathogenesis ([@R3]; [@R17]; [@R18]; [@R34]; [@R41]).

Our study demonstrates that the IL-1β-IL-1 R signaling pathway is essential in dermal γδT cell proliferation and IL-17 production. These effects are through the IL-1R-MyD88-mTOR signaling pathway. A previous study shows that the IL-1R-MyD88 pathway is also critical for GM-CSF production by γδT cells ([@R32]). IL-1β signaling has been shown to play a critical role during the initial stage of Th17 cell differentiation ([@R9]). Previous studies have shown that antigen-specific Th17 cells failed to develop in IL1R-deficient mice ([@R20]). However, γδT17 cells appear to develop normally in the dermis of IL-1R-deficient mice. Similar to Th17 cells, IL-1β also induces phosphorylation of the mTOR in dermal γδT cells. Rapamycin treatment significantly reduces IL-1β-induced dermal γδT cell proliferation and IL-17 production. We show that IL-1β-induced mTOR phosphorylation is completely dependent on adaptor protein MyD88. Notably, mTORC1 and mTORC2 differentially regulate dermal γδT effector function despite the fact that both mTORC1 and mTORC2 pathways are activated in dermal γδT cells upon IL-1β stimulation. We show that IL-1β-induced dermal γδ T cell proliferation and expansion is dependent on both mTORC1 and mTORC2. This is in contrast with a recent study showing enhanced γδT cell generation caused by mTORC1 deficiency ([@R56]). This discrepancy may be explained by γδT cells from different anatomical sites. Indeed, CD2-cre;Raptor^f/f^ mice have higher γδT cells in the lymph nodes (LNs), but no substantial difference in the skin compared with control mice. However, IL-17 production is mainly dependent on mTORC2, but not mTORC1. It is increasingly recognized that mTOR signaling acts as a central regulator of cellular metabolism in many immune cells ([@R27]). γδT17 cells utilize oxidative phosphorylation as an energy fuel. We show that inhibition of PK and IDH abolishes γδT17 cells. Because mitochondria function is closely related to oxidative phosphorylation, we show that respiring mitochondria is reduced in mTORC2-deficient dermal γδT cells, but not in mTORC1-deficient dermal γδT cells. The decreased respiring mitochondria leads to reduced oxidative phosphorylation, and thus diminished IL-17 production in mTORC2-deficient dermal γδT cells. The reduced respiring mitochondria could be caused by excessive production of nitroxide (NO) because NO is known to inhibit oxidative phosphorylation ([@R55]). Our data show that ROS production is elevated in the mTORC2-deficient and MyD88 KO dermal γδ T cells, further supporting this notion.

Previous studies have shown that IL-23 signaling is required for Th17 early activation and acquiring pathogenicity ([@R2]; [@R14]). IL-23 also drives γδT17 cell differentiation and effector function ([@R42]). Here we show that IL-23 synergizes with IL-1β to induce enhanced IL-17 production in dermal γδT cells. This is for both subsets of dermal γδT cells. IL-23 stimulates STAT3 phosphorylation in dermal γδT cells, which is independent of the IL-1R-MyD88-mTOR pathway. However, STAT3 deficiency in dermal γδT cells results in perplexing data by showing decreased γδT cell proliferation and IL-17 production in dermal Vγ4 T cells, but no obvious impact on dermal Vγ6 T cells. A recent study has shown that mouse innate-like αβT cells produce IL-17 independent of STAT3 ([@R50]). These innate αβT cells express transcription factor PLZF, whereas Vγ6 T cells also express a high level of PLZF ([@R31]). Gene expression profiles between Vγ4 and Vγ6 T cells are largely similar, although Vγ6 T cells express higher levels of IL-1R and IL-23R. Notably, IL-1R expression is significantly decreased in STAT3-deficient dermal Vγ4 cells, but not in Vγ6 T cells. This finding may well explain the decreased IL-17 production and proliferation in STAT3-deficient Vγ4 T cells, but not in Vγ6 T cells, upon IL-1β or IL-1β plus IL-23 stimulation. Previous studies have shown that IL-23 induces activation of the STAT3-dependent and STAT3-independent nuclear factor κB (NF-κB) pathway leading to IL-17 production ([@R8]; [@R23]). Indeed, dermal Vγ6 T cells have elevated RelA expression upon stimulation, and this is independent of STAT3 activation ([Figure 6I](#F6){ref-type="fig"}). Thus, it is proposed that IL-17 production from dermal Vγ6 T cells may be through the STAT3-independent RelA/NF-κB pathway.

Transcription factor IRF-4 has been shown to bind and govern chromatin accessibility, leading to recruitment of RORγt and binding to Th17 signature genes ([@R10]; [@R29]). We show that IRF-4 expression in dermal γδ T cells is highly stimulated by IL-1β and is abolished in the Rictor cKO mice, but not in Raptor-deficient mice. In addition, IRF-4 expression is also decreased in STAT3-deficient dermal γδ T cells. These data suggest that IRF-4 could be a link between IL-1R and IL-23R signaling pathways for enhanced IL-17 production. This is in contrast with a previous study showing that IRF-4 is not required for γδ T cell IL-17 production ([@R44]). However, dermal γδ T cells have unique development pathways that may require differential signaling molecules for their functional activation and differentiation ([@R4]). Knockdown of IRF-4 in dermal γδ T cells shows reduced IL-17 production, further supporting this notion. Taken together, we propose that dermal γδT cell effector function is regulated through IL-1R and IL-23R pathways. IL-1β activates IRF-4 through the IL-1R-MyD88-mTOC2 pathway for both subsets of dermal γδT cells. In contrast, IL-23 synergizes with IL-1β to induce increased IRF-4 activation in dermal Vγ4 T cells via a STAT3-dependent pathway, whereas dermal Vγ6 T cells may activate IRF-4 via a STAT3-independent RelA pathway leading to IL-17 production. These findings provide critical molecular insight into understanding dermal γδ T cell effector function in skin inflammation.

It has been shown that mTOR signaling plays a critical role in psoriasis pathogenesis ([@R1]; [@R45]). Activation of mTOR signaling in psoriatic skin, particularly in keratinocytes, has been reported previously ([@R6]). mTOR inhibitors have been tested in the animal models and clinic for the treatment of psoriasis ([@R1]; [@R15]). Preliminary data suggest that blocking mTOR signaling reduces disease severity ([@R54]). However, it has not been tested whether mTOR deficiency in γδT cells impacts on skin inflammation. We show that IMQ-induced skin inflammation and immunohistopathology are significantly reduced in mTORC2-deficient mice. Consistent with *in vitro* observations, *in vivo* spontaneous IL-17 production and proliferation of dermal γδT cells are significantly decreased in Rictor cKO mice. These findings suggest that mTOR inhibition may primarily impact on dermal γδT cells in the IMQ-induced psoriasis-like mouse model. In addition, our recent data show that IL-1β-induced keratinocyte activation is independent of mTOR signaling, further suggesting that mTOR signaling in dermal γδT cells plays a predominant role in skin inflammation ([@R5]). Notably, IMQ-induced skin inflammation is abrogated in the MyD88 KO mice ([@R43]), further suggesting critical roles of the IL-1R/MyD88/mTOR signaling pathway in dermal γδT effector function and skin inflammation. In contrast, IL-23-induced STAT3 activation in dermal γδT cells renders no obvious impact on skin inflammation. This is due to differential signaling requirements for dermal Vγ4 versus Vγ6 T cell effector function. We show that dermal Vγ6 T cell proliferation and IL-17 production are independent of STAT3 both *in vitro* and *in vivo*, suggesting that inhibition of STAT3 may not reduce IMQ-induced skin inflammation. It is worth noting that the CD2-cre deletion system also deletes mTORC1 and mTORC2 from αβ T cells. However, dermal γδ T cells are the major IL-17 producer in the skin. It thus proposes that elevated IL-1β in the skin leads to mTOR activation that synergizes with IL-23 to induce dermal γδT cell expansion and enhanced IL-17 production, leading to subsequent skin inflammation.

STAR★METHODS {#S12}
============

CONTACT FOR REAGENT AND RESOURCE SHARING {#S13}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jun Yan (<jun.yan@buisviNe.edu>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S14}
--------------------------------------

### Mouse models {#S15}

C57BL/6 WT, MyD88^−/−^ and *Il1r1*^−/−^ mice on C57BL/6 background were purchased from the Jackson Laboratory. IL-23R KO mice were imported from Genetech. hCD2-Cre mice (Jackson Laboratory) were crossed with Raptor^fl/fl^ mice, Rictor^fl/fl^ mice (Jackson Laboratory) and Stat3^fl/fl^ mice ([@R13]) to generate CD2-cre;Raptor^fl/fl^, CD2-cre;Rictor^fl/fl^ and CD2-cre;Stat3^fl/fl^ conditional KO (cKO) mice. Male and female mice were used in all experiments (6--12 weeks old) and were housed in specific pathogen free conditions. All experiments were in accordance with institutional guidelines and approved by the IACUC at the University of Louisville.

### Human subjects {#S16}

Patients with psoriasis vulgaris were diagnosed based on the clinical and histopathologic criteria. For RNaseq study, total 21 patients (age, 27--69; female 4, male 17) with psoriasis vulgaris were enrolled. All patients had not been treated systemically for at least 4 weeks or topical treatment for at least 2 weeks prior to the study entry. Patients were treated with topical halomethasone monohydrate 0.05% cream daily for 2 weeks. Skin lesion severity was evaluated by PASI (psoriasis area and severity index) score. A 50% reduction in the PASI score was considered as effective treatment. Typical lesions that represented the overall skin condition before and after treatment were taken. RNAs were extracted and library was made and sequenced with sequencing platform BGISEQ-500 (BGI). The sample sequences were directly aligned to the *Homo sapiens* reference genome assembly using tophat2 (version 2.0.13), generating alignment files. The number of reads is between 37 to 52 million. RNA-Seq data have been deposited into NCBI GEO with the accession number (GSE114729). All participants were recruited from Department of Dermatology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine. These studies were approved by the Shanghai Jiaotong University School of Medicine Research Ethics Committee. All the participants gave their written informed consent.

### Animal procedures {#S17}

#### Establishment of psoriasis-like mouse models {#S18}

Imiquimod (IMQ)-induced psoriasis-like mouse model was established as previously described ([@R4]). Briefly, CD2-cre;Rictor^*f/f*^ and control Rictor^*f/f*^ mice or CD2-cre;Stat3^*f/f*^ and control Stat3^*f/f*^ mice were applied daily with IMQ cream (5%) (Aldara; 3M Pharmaceuticals) on the shaved back for 5 consecutive days. Mice were sacrificed on day 5. The skin samples were embedded and frozen in OCT for H&E and immunohistochemistry (IHC) staining. Additionally, skin samples were excised in TRIzol (Thermo Fisher SCIENTIFIC) for RNA extraction. Skin cell suspensions from IMQ-treated skin were also stained for CD45, Gr-1, CD3, gSTCR and intracellular IL-17 and percentages of CD45^+^Gr-1^+^ cells as well as IL-17 production were determined by flow cytometry.

#### BrdU in vivo incorporation assay {#S19}

CD2-cre;Rictor^*f/f*^ and control Rictor^*f/f*^ mice or CD2-cre;Stat3^*f/f*^ and control Stat3^*f/f*^ mice were applied daily with IMQ cream (5%) (Aldara; 3M Pharmaceuticals) on the shaved back for 5 consecutive days. Mice was intraperitoneally injected BrdU (2 mg/mouse, Millipore Sigma) on day 5. After 24 hours, mouse skin cells from IMQ-treated skin were stained with anti-BrdU antibody (Ab) (clone 3D4, Biolegend) and Brdu^+^ cells were determined by flow cytometry.

#### Skin histology and immunohistochemical (IHC) staining {#S20}

Skin sections from IMQ-treated skin were embedded and frozen in OCT and stained with H&E and Gr-1 mAb for IHC. Epidermal thickness was determined by measuring the average interfollicular distance under the microscope in a blinded manner. For IHC staining, skin cryosections were fixed, blocked and then stained with purified rat-anti-mouse Gr-1 Ab (1:50 dilution) following with goat-anti-rat IgG secondary antibody (1:200 dilution, Southern Biotech). Slides were developed with AEC substrate solution (Vector Laboratories) and then counterstained with hematoxylin. Images were acquired at x200 magnification using Aperio ScanScope digital scanners.

METHOD DETAILS {#S21}
--------------

### Tissue processing, cell culture and stimulation {#S22}

#### Tissue preparation {#S23}

Whole skin cells from mouse back skin were prepared as previously described ([@R3]). Briefly, mouse back skin was cut into small pieces and digested with a buffer containing collagenase IV (Millipore Sigma), hyaluronidase (Millipore Sigma), and DNase-I (Millipore Sigma) at 37°C for 2 hours. The tissue was further homogenized with a syringe and filtered through a 40 μm cell strainer. Whole skin single cell suspensions were obtained by centrifugation. Single cell suspensions from peripheral lymph nodes were prepared by mashing the lymph nodes through 40 μm cell strainers.

#### Establishment of skin γδ T cell line {#S24}

Mouse skin γδ T cell line was generated *in vitro* from whole skin cell suspensions. Briefly, whole skin cell suspensions were prepared as described above. At day 3, purified anti-mouse CD3 antibody (0.1 μg/ml, Biolegend) were added into the culture followed by adding recombinant mouse IL-7 (rmIL-7) (5 ng/ml, Biolegend) on the next day and day 7. Cells were expanded and cultured for total 10--14 days. The percentage of dermal γδ T cells was determined by flow cytometry.

#### Cell sorting {#S25}

Mouse skin γδ T cell lines were established as described above and stained with anti-mouse CD3, γδ TCR and/or Vγ4 Abs. Skin γδ T cells or skin Vγ4^+^ orVγ4^−^T cells were sorted by MoFlow high-speed sorter or BD FACSAria III cell sorter for western blot analysis or real-time PCR.

#### Cell stimulation {#S26}

Whole skin cell suspensions were stimulated with rmIL-23 (5ng/ml, Biolegend), rmIL-1β (10ng/ml, Biolegend), or rmIL-23 plus rmIL-1β for indicated times. Intracellular IL-17 was measured by flow cytometry. In proliferation assay, whole skin cells were labeled with CFSE (1 μM, Thermo Fisher SCIENTIFIC) and then stimulated with rmIL-23, rmIL-1β, or rmIL-23 plus rmIL-1β for 3 days. Cell proliferation and intracellular IL-17 were measured by flow cytometry. For Rapamycin inhibition assay, whole skin cell suspensions were stimulated with mouse rmIL-23 plus rmIL-1β for 3 days in the absence or presence of Rapamycin (Millipore Sigma). In metabolic inhibition experiments, AGI-5198 (Millipore Sigma), sodium oxalate (Millipore Sigma), and 2-DG (Millipore Sigma) were added in the culture at indicated concentrations. For NAC assay, skin γδ T cell lines were stimulated with rmIL-1β and rmIL-23 in the varying concentrations of NAC for 24 h and intracellular IL-17 was determined by flow cytometry. In addition, whole skin cells or lymphocytes were also stimulated with PMA plus ionomycin for 5 hours in the presence of Golgi-Plug. Whole skin cells from IMQ-treated skin were incubated with Golgi-Plug only at 37°C for 5 hours. Intracellular IL-17 level was determined by flow cytometry. In dermal γδ T cell signaling studies, mouse skin γδ T cell line or sorted skin Vγ4^+^ or Vγ4^−^ from skin γδ T cell line was stimulated with rmIL-23, rmIL-1β, or rmIL-23 plus rmIL-1β for indicated times. Phosphorylation of indicated molecules was measured by flow cytometry or western blot analysis. mRNA levels of transcriptional factor IRF4 and IL-1R were also determined by real-time quantitative PCR (qPCR) analysis.

#### IRF4 siRNA transfection {#S27}

Primary skin γδ T cell lines were seeded into 24-well plates with RPMI-1640 containing 20% FBS and mIL-7 (3ng/ml, Biolegend) for overnight culture. FITC-conjugated control siRNA (sc-36869, Santa Cruz Biotechnology) or IRF4 siRNA (sc-35713, Santa Cruz Biotechnology) was added into the culture with lipofetcamine™2000 reagent (11668--027, Thermo Fisher SCIENTIFIC). A small amount of FITC-conjugated siRNA was added into the IRF4 siRNA transfection well. After 5 hours incubation, fresh RPMI-1640 medium containing 3 ng/ml mIL-7 was added and cells were continued to culture for additional 24 hours. Cells were then stimulated with mIL-1β (10ng/ml) and mIL-23 (10ng/ml) for 48 hours and intracellular IL-17 staining was performed. Transfected cells positive for FITC-conjugated siRNA were gated for flow analysis as described previously ([@R49]).

#### Flow cytometry {#S28}

All utilized Abs are summarized in the [Key Resources Table](#T1){ref-type="table"}. Samples were harvested with BD FACS Canton (Becton Dickinson, San Jose, CA, USA) and analyzed with FlowJo software (TreeStar).

#### Surface staining and intracellular staining {#S29}

For surface staining, cells were first blocked with anti-CD16/32 (clone 2.4G2) and then stained with different cell surface Abs at 4°C for 20min. The relevant isotype control mAbs were also used. For intracellular cytokine staining, cells were stained with surface Abs first. Then cells were fixed and permeabilized (Biolegend) followed by intracellular staining for IL-17 at 4°C for 45min.

#### Phospho flow staining {#S30}

For phospho-Stat3 (p-Stat3), p-AKT and p-S6 Ribosomal protein flow staining, mouse skin cells were fixed in 4% paraformaldehyde and then permeabilized in 90% cold methanol. Cells were stained with rabbit-anti-mouse p-Stat3 (Tyr705), p-AKT (Ser473) or p-S6 Ribosomal protein (Ser235/236) (Cell Signaling Technology) at 4°C overnight. For phospho-mTOR staining, cells were fixed in 4% paraformaldehyde and then permeabilized in Tween-20. Cells were stained with rabbit-anti-mouse p-mTOR (Ser2448, Abcam) at 4°C overnight. On next day, cells were washed and stained with fluorochrome-labeled donkey anti-rabbit IgG Ab, anti-mouse CD3, γδ TCR and Vγ4 at room temperature for 30min.

#### Measurement of mitochondrial content {#S31}

For MitoTracker Green and MitoTracker Red staining, fresh mouse skin cells or stimulated skin cells were suspended in prewarmed PBS with 0.1% BSA. Cells were first blocked with anti-CD16/32 and then stained with MitoTracker Green (Thermo Fisher SCIENTIFIC, 80nM) and MitoTracker Red (Thermo Fisher SCIENTIFIC, 20nM) at 37°C for 30min. Cells were then stained with different cell surface Abs at 4°C for 20 min. For MitoSOX staining, fresh mouse skin cells or stimulated skin cells were suspended in prewarmed PBS with 0.1%BSA. Cells were stained with MitoTracker Green (80nM) and incubated at 37°C for 30 min. Cells were washed with prewarmed HBSS including Ca^2+^ and Mg^2+^ and stained with MitoSOX (Thermo Fisher SCIENTIFIC, 5 μM) at 37°C for 15min. Cells were then stained with different cell surface Abs at 4°C for 20 min. For DCFDA-Cellular Reactive Oxygen Species (ROS) staining, cells were first blocked with anti-CD16/32 and then stained with DCFDA (Abcam, 20 μM) at 37°C for 30min. Cells were washed and stained with different cell surface Abs at 4°C for 20 min.

#### Brdu staining {#S32}

Mouse skin cells from IMQ-treated skin were stained with viability dye, anti-mouse CD3, γδ TCR, Vγ4, Vγ6 and CD45. After fixation and treatment with DNase I (Millipore Sigma), cells were stained with anti-mouse BrdU Ab (clone 3D4, Biolegend) and then measured by flow cytometry.

#### Immunofluorescence (IF) staining {#S33}

Sorted mouse CD45^+^CD4^−^CD8^−^cells from C57BL/6 WT cultured skin γδ T cell lines were stimulated with rmIL-23 (5ng/ml) or rmIL-1β (10ng/ml) at 37°C for 30min. Cells were fixed with 4% paraformaldehyde and then permeabilized with 0.3% (v/v) Triton X-100. Cells were incubated with anti-γδTCR (Biolegend) and anti-p-Stat3 (Tyr705, Cell Signaling Technology) or anti-p-mTOR (Ser2448, Abcam) at 4 °C overnight followed by donkey anti-rabbit secondary Ab and DAPI for nucleus. Images were acquired with fluorescence microscope (Nikon).

#### Western blot analysis {#S34}

For immunoblot analysis, mouse skin γδ T cells or skin Vγ4^+^ and Vγ4^−^ T cells were sorted from cultured skin γδ T cell line and stimulated with rmIL-1β, rmIL-23, rmIL-1β plus rmIL-23 for indicated times. Cells were lysed in Triton X-100 lysis buffer containing protease and phosphatase inhibitors. The whole-cell extracts were separated by SDS-PAGE and electrotransferred to a polyvinylidene difluoride membrane. After blocking, the membranes were probed overnight at 4°C with appropriate primary Abs and then secondary Ab. The primary Abs included p-Stat3 (Tyr705), p-AKT (Ser473), p-S6 Ribosomal protein (Ser235/236), and p-mTOR (Ser2448) (Cell Signaling Technology). The blots were developed using ECL Plus western blotting Detection Reagents (GE Healthcare).

#### RNA extraction and real-time quantitative PCR (qPCR) {#S35}

RNAs were isolated using a QIAGEN RNeasy kit according to the manufacturer's instructions (QIAGEN) or TRIzol (Thermo Fisher SCIENTIFIC). After reverse transcription into cDNA with a Reverse Transcription Kit (Bio-Rad), qPCR was then performed on Bio-Rad CFX Connect™ Real-time system (Bio-Rad) using SYBR Green (Bio-Rad) and gene-specific primers were listed as follows: mouse IL-17A (Mm_Il17a_SG, QIAGEN) were purchased from QIAGEN; other primers were described in the [Key Resources Table](#T1){ref-type="table"}. Mouse gene expression level was normalized to mouse β−2 microglobulin (β-MG) housekeeping gene and represented data as fold differences by the 2^−ΔΔCt^ method, where ΔCt = Ct(target gene)-Ct(β-MG) and ΔΔCt = ΔCt(induced)-ΔCt(reference).

QUANTIFICATION AND STATISTICAL ANALYSIS {#S36}
---------------------------------------

### Statistical analysis {#S37}

All quantitative data are shown as mean ± s.e.m unless otherwise indicated. All samples were compared using two-tailed, unpaired Student's T test or one-way ANOVA if more than two groups were compared. A *P value* less than 0.05 was considered significant. Statistical analysis was performed with GraphPad Prism software.
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![Dermal γδT Cell Activation Requires Both IL-1R and IL-23R Signaling Pathways\
(A) Gene set enrichment analysis identifies transcriptional downregulation of the IL-12 production regulatory pathway and IL-1R pathway in psoriasis patients effectively treated with glucocorticoid. The top 10 leading edge genes in these two pathways are shown.\
(B) Whole skin cell suspensions from WT, IL-1R KO, and IL-23R KO mice were labeled with CFSE and stimulated with IL-23, IL-1β, or IL-23 plus IL-1β for 3 days. Cell proliferation and intracellular IL-17 were analyzed by flow cytometry. Flow plots gated on CD3^+^γδTCR^int^Vγ4 or CD3^+^γδTCR^int^Vγ6 cells are representative of at least two independent experiments with similar results. Each experiment includes at least three mice from WT, IL-1R KO, or IL-23R KO strains.\
(C) Summarized percentages of dermal γδT17 cells are shown as mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 (unpaired Student's t test).\
(D) Summarized dermal γδT cell proliferation with different subsets of dermal γδT cells (Vγ4 and Vγ6) is shown as mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 (unpaired Student's t test).](nihms-1531460-f0002){#F1}

![IL-1β-Induced Dermal γδ T Cell Activation Is Dependent on the mTOR-Mediated Signaling Pathway\
(A and B) Cultured skin γδT cell lines from C57BL/6 WT mice were stimulated with IL-23 and/or IL-1β for 30 min. p-STAT3 and p-mTOR were examined by flow cytometry (A) or western blot (B) analysis. Flow histograms gated on CD3^+^γδTCR^+^ cells are representative of at least three independent experiments with similar results. Each experiment includes at least two mice. Western blot analysis is representative of two independent experiments with similar results.\
(C) CD45^+^CD4^−^CD8^−^ cells were sorted from cultured C57BL/6 WT skin γδT cell lines and then stimulated with IL-23 or IL-1β for 30 min. Cells were stained with fluorochrome-labeled γδTCR (red) and p-mTOR (green) or p-STAT3 (green) with DAPI (blue). Representative images are shown. Scale bar: 10 μm.\
(D) Cultured skin γδT cell lines from WT, IL-1R KO, and IL-23R KO mice were stimulated with IL-23 or IL-1β for 30 min. p-STAT3 and p-mTOR were examined by flow cytometry. Flow histograms gated on CD3^+^γδTCR^+^ cells are representative of at least two independent experiments with similar results. Each experiment includes at least three mice from WT, IL-1R KO, or IL-23R KO strains.\
(E) Whole skin cell suspensions from WT mice were labeled with CFSE and then stimulated with IL-23 plus IL-1β in the presence or absence of rapamycin for 3 days. CFSE dilution and intracellular IL-17 production by dermal γδT cells were determined by flow cytometry. Flow plots gated on CD3^+^γδTCR^int^ cells are representative of at least three independent experiments with similar results. Each experiment includes at least three C57BL/6 WT mice. Proliferated dermal γδT cells and percentages of IL-17-producing γδT cells are shown as mean ± SD. \*\*p \< 0.01, \*\*\*p \< 0.001 (one-way ANOVA).](nihms-1531460-f0003){#F2}

![mTORC2-Mediated Signaling Pathway Is Critical in IL-1β-Induced Dermal γδT Cell Activation\
(A and B) Sorted Vγ6 (Vγ4^−^) or Vγ4T cells from cultured skin γδT cell lines were stimulated with IL-1β for 30 min. p-AKT and p-S6 were examined by western blot (A) or flow cytometry (B). Western blot analysis is representative of two independent experiments with similar results. Flow histograms gated on CD3^+^γδTCR^+^ cells are representative of at least three independent experiments with similar results. Each experiment includes at least two WT mice.\
(C) Schematic of mTORC2 with representative histogram showing abolished mTORC2 activity (p-AKT) in Rictor-deficient dermal γδT cells upon IL-1β stimulation. Flow histogram was gated on CD3^+^γδTCR^+^ cells.\
(D) Whole skin cell suspensions from CD2-cre;Rictor^*f/f*^ or control Rictor^*f/f*^ mice were labeled with CFSE and then stimulated with IL-1β or IL-23 plus IL-1β for 3 days. CFSE dilution by dermal γδT cells was determined by flow cytometry. Flow plots gated on CD3^+^γδTCR^int^ cells are representative of at least three independent experiments with similar results. Each experiment includes at least two mice from CD2-cre;Rictor^*f/f*^ or control Rictor^*f/f*^ strains. Proliferated dermal γδ T cells are shown as mean ± SEM. \*\*p \< 0.01, \*\*\*p \< 0.001 (unpaired Student's t test).\
(E) Whole skin cell suspensions from CD2-cre;Rictor^*f/f*^ or control Rictor^*f/f*^ mice stimulated with IL-23 plus IL-1β at Indicated time points and Intracellular IL-17 production by dermal γδT cells were assessed by flow cytometry. Flow plots gated on CD3^+^γδTCR^int^ cells are representative of at least three independent experiments with similar results. Each experiment includes at least two mice from CD2-cre;Rictor^*f/f*^ or control Rictor^*f/f*^ strains. Percentages of IL-17-producing γδT cells are shown as mean ± SEM. \*\*p \< 0.01, \*\*\*p \< 0.001 (unpaired Student's t test).\
(F) Cultured skin γδT cell lines from CD2-cre;Rictor^*f/f*^ or control Rictor^*f/f*^ mice and CD2-cre;Raptor^*f/f*^ or control Raptor^*f/f*^ were stimulated with IL-23 for 30 min. p-STAT3 was examined by flow cytometry. Flow histograms gated on CD3^+^γδTCR^+^ cells are representative of at least three independent experiments with similar results. Each experiment includes at least two mice from CD2-cre;Rictor^*f/f*^ or control Rictor^*f/f*^ and CD2-cre;Raptor'^7^' or control Raptor^*f/f*^ strains.](nihms-1531460-f0004){#F3}

![mTORC2 Deficiency in Dermal γδT Cells Leads to Accumulation of Dysfunctional Mitochondria and Production of Mitochondria ROS\
(A) γδT cell lines from C57BL/6 WT mice were stimulated with phorbol 12-myristate 13-acetate (PMA)+ionomycin in the presence of varying concentrations of 2-DG, OXA, or AGI for 24 h. Intracellular IL-17 and IFN-γ were examined by flow cytometry. Flow plots gated on CD3^+^γδTCR^+^ cells are representative of at least three independent experiments with similar results. Each experiment includes at least three WT mice.\
(B) Sorted skin Vγ4 or Vγ6 (Vγ4^−^) T cells from cultured γδT cell lines established from CD2-cre;Rictor^*f/f*^ or control Rictor^*f/f*^ mice were blotted with indicated molecules including HIF-1α, PFKFB3, IDH2, and HK1.\
(C) Whole skin cell suspensions from CD2-cre;Rlctor^*f/f*^ or control Rictor^*f/f*^ mice and CD2-cre;Raptor^*f/f*^ or control Raptor^*f/f*^ were stained with 2-NBDG. Expression of 2-NBDG was analyzed by flow cytometry. Flow histograms gated on CD3^+^γδTCR^int^ cells are representative of at least three independent experiments with similar results. Each experiment includes at least two mice from each strain.\
(D) Whole skin cell suspensions from CD2-cre;Rictor^*f/f*^ or control Rictor^*f/f*^ mice and CD2-cre;Raptor^*f/f*^ or control Raptor^*f/f*^ were stained with MitoTracker Green and MitoTracker Red. Flow plots gated on CD3^+^γδTCR^int^ cells are representative of at least three independent experiments with similar results. Each experiment includes at least two mice from each strain. Percentages of MitoTracker Green^+/hi^ and MitoTracker Red+ dermal γδT cells are shown as mean ± SEM. \*\*p \< 0.01 (unpaired Student's t test).\
(E and F) Whole skin cell suspensions from CD2-cre;Rictor^*f/f*^ or control Rictor^*f/f*^ mice were stained with MitoSOX for mitochondria ROS production (E) and DCFDA for total ROS production (F). Flow plots (E) or histograms (F) gated on CD3^+^γδTCR^int^ cells are representative of at least two independent experiments with similar results. Each experiment includes at least two mice from CD2-cre;Rictor^*f/f*^ or control Rictor^*f/f*^ strains. Percentage of MitoSOX^+^(E) and mean fluorescence intensity (MFI) of DCFDA^+^ (F) dermal γδ T cells are shown as mean ± SEM. \*p \< 0.05 (unpaired Student's t test).\
(G) Skin γδT cell lines from Rictor cKO mice were stimulated with IL-1β plus IL-23 in the presence of varying concentrations of NAC for 24 h. Intracellular IL-17 was examined by flow cytometry. Flow plots gated on CD3^+^γδTCR^+^ cells are combined from two independent experiments with similar results. Data are shown as mean ± SD. \*p \< 0.05, \*\*p \< 0.01 (one-way ANOVA).](nihms-1531460-f0005){#F4}

![STAT3 Signaling Differentially Regulates Effector Function of Different Subsets of Dermal γδT Cells\
(A) Whole skin cell suspensions from CD2-cre;Stat3^*f/f*^ or control Stat3^*f/f*^ mice were stimulated with IL-1β, IL-23, or IL-23 plus IL-1β for 48 h. Intracellular IL-17 production by dermal γδT cells was determined by flow cytometry. Flow plots gated on CD3^+^γδTCR^int^ cells, Vγ4, or Vγ6 T cells are representative of at least three independent experiments with similar results. Each experiment includes at least two mice from CD2-cre;Stat3^*f/f*^ or control Stat3^*f/f*^ strains. Percentages of total γδT17, Vγ4T17, and γδ6T17 cells are shown as mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 (unpaired Student's t test).\
(B) Cultured skin γδT cell lines from CD2-cre;Stat3^*f/f*^ or control Stat3^*f/f*^ mice were stimulated with IL-23 or IL-1β for 30 min. p-Stat3, p-mTOR, p-AKT, and p-S6 were examined by flow cytometry. Flow histograms gated on CD3+γδTCR+Vγ4 or CD3+γδTCR+Vγ6 cells are representative of at least three independent experiments with similar results. Each experiment includes at least two mice from CD2-cre;Stat3^*f/f*^ or control Stat3^*f/f*^ strains.](nihms-1531460-f0006){#F5}

![Transcription Factor IRF-4 Links IL-1R and IL-23R Pathways for Enhanced IL-17 Production in Dermal γδT Cells\
(A) Differential gene expression in immature fetal Vγ4T17 cells and Vγ6T17 cells (1.5-fold cutoff).\
(B) Immature fetal Vγ6T17 cells express higher mRNA levels of *IL-1r, IL-23r,* and *IL-7r* than Vγ4T17 cells.\
(C) Skin single-cell suspensions were stained for IL-1R and IL-23R on dermal Vγ4 and Vγ6 T cells. Flow plots gated on CD3^+^γδTCR^int^Vγ4 or CD3^+^γδTCR^int^Vγ6 cells are representative of at least two independent experiments with similar results.\
(D) Sorted Vγ4 and Vγ6 T cells from cultured CD2-cre;Stat3^*f/f*^ or control Stat3^*f/f*^ skin γδ T cell lines were stimulated with IL-23 or IL-23 plus IL-1β for 3h. The IL-1R mRNA expression levels were determined by real-time PCR analysis. Summarized data are representative of at least two independent experiments with similar results. Each experiment includes at least two mice from each strain. Data are shown as mean ± SEM. \*\*p \< 0.01, \*\*\*p \< 0.001 (unpaired Student's t test).\
(E) IL-1R expression levels on dermal Vγ4 and Vγ6 T cells from CD2-cre;Stat3^*f/f*^ or control Stat3^*f/f*^ mice were assessed by flow cytometry. Flow histograms gated on CD3^+^γδTCR^int^ Vγ4 or CD3^+^γδTCR^int^Vγ6 cells are representative of at least three independent experiments with similar results. Each experiment includes at least two mice from CD2-cre;Stat3^*f/f*^ or control Stat3^*f/f*^ strains.\
(F) Sorted Vγ4 and Vγ6T cells from cultured CD2-cre;Stat3^*f/f*^ or control Stat3^*f/f*^ skin γδT cell lines were stimulated with IL-23 or IL-23 plus IL-1β for 3 h. The IRF-4 mRNA expression levels were determined by real-time PCR analysis. Summarized data are representative of at least three independent experiments with similar results. Each experiment includes at least three mice from each strain. Data are shown as mean ± SEM. \*p \< 0.05 (unpaired Student's t test).\
(G) Sorted γδT cells from cultured CD2-cre;Rictor^*f/f*^ or control Rictor^*f/f*^ mice and CD2-cre;Raptor^*f/f*^ or control Raptor^*f/f*^ γδ T cells were stimulated with IL-1β for 3 h, and the IRF-4 mRNA expression levels were determined by real-time PCR analysis. Summarized data are representative of at least three independent experiments with similar results. Each experiment includes at least two mice from each strain. Data are shown as mean ± SEM. \*p \< 0.05 (unpaired Student's t test).\
(H) Cultured dermal γδT cells from WT mice were transfected with IRF-4 siRNA and/or fluorescein isothiocyanate (FITC)-labeled control siRNA. Cells were then stimulated with IL-1β plus IL-23 for intracellular IL-17 production. Flow plots gated on CD3^+^γδTCR^+^ cells are representative of at least three independent experiments with similar results. Percentages of IL-17-producing γδT cells are shown as mean ± SEM. \*\*p \< 0.01 (unpaired Student's t test).\
(I) Sorted Vγ6T cells from cultured CD2-cre;Stat3^*f/f*^ or control Stat3^*f/f*^ skin γδT cell lines were stimulated with IL-23 plus IL-1β for 3 h. The RelA mRNA expression levels were determined by real-time PCR analysis. Summarized data are representative of at least two independent experiments with similar results. Data are shown as mean ± SEM. \*\*p \< 0.01, \*\*\*p \< 0.001 (unpaired Student's t test).](nihms-1531460-f0007){#F6}

![IMQ-Induced Skin Inflammation Is Significantly Reduced in mTORC2-Deficient Mice\
(A) CD2-cre;Rictor^*f/f*^ or control Rictor^*f/f*^ mice (n = 3) were treated daily for 5 days with IMQ. Representative H&E-stained sections and frozen sections stained with Gr-1 are shown. Gr-1-positive cells are brown. Skin tissues were also stained with CD45 and Gr-1 assessed by flow cytometry. Epidermal thickness at day 5 and percentage of CD45^+^Gr-1^+^ cells were measured. Scale bar, 100 μm. Data are representative of three independent experiments with similar results. Data are shown as mean ± SEM. \*p \< 0.05, \*\*\*p \< 0.001(unpaired Student's t test).\
(B) The mRNA levels of IL-17 and TNF-α from skin tissues were measured by real-time PCR analysis. Data are shown as mean ± SEM. \*p \< 0.05 (unpaired Student's t test).\
(C) CD2-cre;Stat3^*f/f*^ or control Stat3^*f/f*^ mice (n = 3--4) were treated daily for 5 days with IMQ. Representative H&E-stained sections and frozen sections stained with Gr-1 are shown. Gr-1-positive cells are brown. Scale bar, 100 μm.\
(D and E) CD2-cre;Rictor^*f/f*^ or control Rictor^*f/f*^ mice (D) and CD2-cre;Stat3^*f/f*^ or control Stat3^*f/f*^ mice (E) were applied topically with IMQ for 5 days. BrdU were injected 1 day before mice were sacrificed. Skin single-cell suspensions were stained for BrdU expression and spontaneous IL-17 production without stimulation. Flow plots gated on CD3^+^γδTCR^int^Vγ4 or CD3^+^γδTCR^int^Vγ6 cells are representative of two independent experiments with similar results. Percentages of BrdU^+^Vγ4^+^ cells and BrdU^+^Vγ6^+^ cells and percentages of IL-17-producing Vγ4 and Vγ6 T cells are shown as mean ± SEM. \*p \< 0.05, \*\*p \< 0.01 (unpaired Student's t test).](nihms-1531460-f0008){#F7}
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###### Highlights

-   Dermal gamma-delta T cell effector function relies on IL-1R and IL-23R pathways

-   mTORC2 is essential for dermal gamma-delta T17 cell function and skin inflammation

-   STAT3 signaling is critical for dermal Vγ4 T cell function, but not for Vγ6 T cells

-   IRF-4 links IL-1β and IL-23 signaling for dermal gamma-delta T cell IL-17 production
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